IGA NEPHROPATHY
Clinical trials for IGA NEPHROPATHY explained in plain language.
Never miss a new study
Get alerted when new IGA NEPHROPATHY trials appear
Sign up with your email to follow new studies for IGA NEPHROPATHY, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New drug aims to slow kidney disease in IgA nephropathy patients
Disease control OngoingThis study tests a drug called BION-1301 in 383 adults with IgA nephropathy, a kidney disease that can lead to kidney failure. The goal is to see if the drug can slow the loss of kidney function over two years compared to a placebo. Participants receive either the drug or a place…
Matched conditions: IGA NEPHROPATHY
Phase: PHASE3 • Sponsor: Novartis Pharmaceuticals • Aim: Disease control
Last updated Jun 16, 2026 12:52 UTC
-
New drug shows promise in slowing kidney disease progression
Disease control OngoingThis study tests an oral drug called atrasentan in 103 adults with kidney diseases that cause protein leakage in urine, such as IgA nephropathy and FSGS. The goal is to see if atrasentan can lower protein levels and protect kidney function over 12 to 30 weeks. Participants must a…
Matched conditions: IGA NEPHROPATHY
Phase: PHASE2 • Sponsor: Novartis Pharmaceuticals • Aim: Disease control
Last updated Jun 08, 2026 13:13 UTC
-
New hope for kidney disease: drug aims to slow damage in IgA nephropathy
Disease control OngoingThis phase 3 study tests the drug atacicept in 376 adults with IgA nephropathy, a kidney disease that can lead to kidney failure. The goal is to see if atacicept can reduce protein in the urine and slow the decline in kidney function compared to a placebo. Participants must have …
Matched conditions: IGA NEPHROPATHY
Phase: PHASE3 • Sponsor: Vera Therapeutics, Inc. • Aim: Disease control
Last updated Jun 08, 2026 13:09 UTC
-
New hope for kidney disease: experimental drug BION-1301 enters human trials
Disease control OngoingThis study tests an experimental drug called BION-1301 in healthy volunteers and people with IgA nephropathy, a kidney disease. The goal is to check the drug's safety and how the body processes it. About 103 participants will be involved in this early-stage trial.
Matched conditions: IGA NEPHROPATHY
Phase: PHASE1, PHASE2 • Sponsor: Novartis Pharmaceuticals • Aim: Disease control
Last updated May 29, 2026 14:16 UTC